Navigation Links
Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
Date:9/13/2007

>

At 9:45 a.m. Eastern Time today, September 13, Isis will conduct a live webcast conference call to discuss this transaction. Interested parties may access the webcast at http://www.isispharm.com or listen to the call by dialing 800-289-0544. A replay will be available for a limited time at the same address.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for cancer, and inflammatory and other diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

Forward-Looking Statement

This press release includes forward-looking statements regarding Isis' collaboration with Ortho-McNeil, Inc. and its affiliates, and discovery and development of drugs for diabetes and metabolic diseases, including ISIS 325568, ISIS 377131, and drugs against undisclosed additional research targets. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and c
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. WARF enters licensing agreements for stem cell products
2. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
3. Software company enters health space with RFID solutions on hold
4. Lucigen Corp. enters global licensing agreement
5. Call centers and customer service: The good, the bad, and the clueless
6. GE Healthcare enters agreement with Canadian health authority
7. Data centers: Buyers beware of over-hyped facilities
8. Data centers: Blowing smoke and raising red flags
9. Prodesse enters patent agreement with Roche
10. UW-Madison enters Kauffman grant competition
11. Applied Technology Centers to aid printing and manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)Alberta Centre for Advanced Micro Nano Technology Products (ACAMP) hosts, health & medical seminar, , EDMONTON, Dec. 4 /PRNewswire/ - Today ACAMP hosted a health & medical seminar, explaini
(Date:12/4/2009)IRVINE, Calif., Dec. 4 BlueFire Ethanol Fuels, Inc. (OTC Bulletin Board: BFRE), a company focused on changing the world,s transportation fuel paradigm through the production of ethanol from non-food
(Date:12/3/2009)MELVILLE, N.Y., Dec. 3 Nikon Corporation, an innovator of advanced optical instruments, announced today that it has signed a licensing agreement with Harvard University granting Nikon the rights to u
(Date:12/3/2009)SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today anno
Breaking Biology Technology:Alberta companies delivering new products to the health & medical marketplace 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4
...Robert H. Norton, MBA, PE, President of Norton &am...vestment, and Carbon Technology Management with th... a new holding corporation, US Property Portfolio,...tion funding for liquidated failed commercial prop...ons, Norton & Associates Inc. provides P &...
...an. 2 Bionovo, Inc.,(Nasdaq: BNVI ) announced t...atory elements that can be used to identify estrog...Molecular and Cellular Endocrinology, showed,that ...trogenic,pharmacological activity exerted by diffe...ion of specific tissue effect. , "Selective es...
...The online medical equipment specialists at Medica...vailability of a brand new item on their website, ... San Diego, CA (PRWEB) December ... announce the release of a brand new Philips Heart...y pieces of discounted and used medical equipment...
Other Biology Technology:Norton & Associates Inc. Adds $3bnUSD Commercial Real Estate Investment P & L Management Holding Group; US Property Portfolio Inc. 2Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform 2Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform 3Medical Machines Online Announces Release of a Brand New Philips HeartStart AED Defibrillator 2Medical Machines Online Announces Release of a Brand New Philips HeartStart AED Defibrillator 3
(Date:12/4/2009)Scientists from the Royal Botanic Gardens, Kew and the Natural History Museum believe that carnivorous behaviour in plants is far more widespread than previously thought, with many commonly grown plan
(Date:12/4/2009)Using a new mathematical model of heart cells, University of Iowa investigators have shown how activation of a critical enzyme, calmodulin kinase II (CaM kinase), disrupts the electrical activity of h
(Date:12/3/2009)In the 1980s, Harald zur Hausen and his co-workers discovered that specific types of human papillomavirus (HPV) cause cervical cancer. Scientists soon found out how these pathogens cause cells to dege
Breaking Biology News(10 mins):Scientists think 'killer petunias' should join the ranks of carnivorous plants 2U-Iowa study helps advance heart-related research 2Papillomavirus silences innate immune response 2Regence Wins Four Telly Awards for Health and Wellness Videos 52468 1Regence Wins Four Telly Awards for Health and Wellness Videos 52468 2Orexigen 28R 29 Therapeutics Announces Proposed Public Offering of Common Stock 52464 1Orexigen 28R 29 Therapeutics Announces Proposed Public Offering of Common Stock 52464 2Obama Puts Politics Before Principle in Abortion Coverage Says Religious Coalition for Reproductive Choice President 52459 1Obama Puts Politics Before Principle in Abortion Coverage Says Religious Coalition for Reproductive Choice President 52459 2
...y Professor of Psychology Dr. Jeffrey Mogil shows ...d but unproven even among higher primates, is also... online June 29 in the journal Science, Professor ...lleagues in the Pain Genetics Lab at McGill Univer...t is, familiar to each other) and able to see one ...
...that the expression of two novel genes within the ... allow identification of women who are and are not.... Results of the study are published in the April...3 and IL17BR gene profile was previously discovere...ptor positive breast cancer treated with tamoxifen...
... the plant hormone auxin for decades, but how plan...anding mystery. Now researchers at the University... which has valuable applications in agriculture. ... journal Genes and Development, describes the disc...that each gene is switched on at a distinct locati...
Other Biology News:Mayo Clinic study finds two genes predict outcome for breast cancer patients 2UC San Diego biologists solve plant growth hormone enigma 2UC San Diego biologists solve plant growth hormone enigma 3
Mouse Oligodendrocyte Differentiation Kit from R&D Systems
Goat Anti-VAP-1 (S-13) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
...atoms at the 3, 3', 4, and 4' positions. It is int...tification of Prostaglandin E2 (PGE2) by GC- or LC...looxygenase products of arachidonic acid and one o... activity influences inflammation, fertility and p...
Site-directed Mutagenesis from Exon BioSystems
Biology Products: